Media
April 2, 2024
Tissue & Cell Technologies Announces Latest NHS Customer - Royal Free, London
The company is delighted to announce that the Breast Unit at London’s world leading Royal Free London NHS Foundation Trust hot on the heals of Addenbrooke’s Hospital two weeks ago.The Royal Free has a worldwide reputation as one England’s top teaching hospitals and a leader in cancer care. The Breast Unit manages one of the largest breast cancer and reconstruction caseloads in the UK. The surgical head, Mr Ash Mosahebi, and his team have expressed strong interest in introducing the company’s fat storage service into their breast reconstruction workflow and bring its benefits to patients and believe it will have enormous benefits for patients as well as helping tackle the substantial waiting list.
The Company’s Chairman & CEO, Antony Rabar, said, “the Royal Free has been in discussions with us since before the covid outbreak and we are delighted that we have finally been able to complete the onboarding process with them. The standard of care and research at the Royal Free make this an ideal department for T&CT’s fat and tissue storage service and technology.”
The service should be available by September 2024.
About Tissue Cell Technologies Tissue Cell Technologies is the leader in human tissue and cell preservation and storage technologies. It has developed the capability to safely process and store large volumes of tissue, over extended periods of time while maintaining unprecedented high viability rates of 75-85%. The T&CT product portfolio includes Regenerys XL® for reconstructive surgery, Regenerys ml® for aesthetic procedures and LipoStor® for long term personalized stem cell bio-insurance. Its first commercial clinical application was with Regenerys XL® for the storage of large volumes of autologous fat for reconstructive surgeries (mainly breast) significantly reducing costs, improving hospitals’ and doctors’ procedures while reducing risk and complications, along with major benefits to patients. With the extension of the technology’s application to other cell types, including skin, heart muscle cells, etc.) the full potential of tissue storage in regenerative medicine and personalized medicine can be realized. For more information, please visit tissueandcell.tech
About Tissue Cell Technologies Tissue Cell Technologies is the leader in human tissue and cell preservation and storage technologies. It has developed the capability to safely process and store large volumes of tissue, over extended periods of time while maintaining unprecedented high viability rates of 75-85%. The T&CT product portfolio includes Regenerys XL® for reconstructive surgery, Regenerys ml® for aesthetic procedures and LipoStor® for long term personalized stem cell bio-insurance. Its first commercial clinical application was with Regenerys XL® for the storage of large volumes of autologous fat for reconstructive surgeries (mainly breast) significantly reducing costs, improving hospitals’ and doctors’ procedures while reducing risk and complications, along with major benefits to patients. With the extension of the technology’s application to other cell types, including skin, heart muscle cells, etc.) the full potential of tissue storage in regenerative medicine and personalized medicine can be realized. For more information, please visit tissueandcell.tech
March 20, 2024
Tissue & Cell Technologies Announces Latest NHS Customer - Addenbrooke’s Hospital, Cambridge
Tissue & Cell Technologies is delighted to announce that the Breast Unit at Cambridge’s world- leading Addenbrooke’s Hospital will be the company’s next major NHS client.
Addenbrooke’s is the East of England’s major hospital trust and trauma centre. The Breast Unit is one of the most advanced in the UK and manages one of the largest caseloads in breast cancer and reconstruction in the UK. The surgical head, Mr Amit Agrawal, and his team have expressed strong interest in introducing the company’s fat storage service into their breast reconstruction workflow and bring its benefits to patients.
The Company’s Chairman & CEO, Antony Rabar, said, “Addenbrooke’s Hospital is a true leader in the field of onco-plastic and reconstructive surgery in the UK with a strong interest in continuous improvement in patient care and improved procedures. The use of fat storage has substantial benefits for hospitals and surgeons, including substantial cost savings as well as delivering improved patient outcomes and satisfaction. Hundreds of women each year undergo life changing reconstructive procedures at the Breast Unit and we are proud that Tissue & Cell Technologies will now be able to provide our world leading fat storage technology to women undergoing reconstructive surgery at Addenbrooke’s, so that they can benefit from using their own all-natural fat in their procedures. We also look forward to collaborating with the team on a number of studies and research as we continue to make advances in clinical outcomes and patient satisfaction.”
The service should be available by September 2024.
Addenbrooke’s is the East of England’s major hospital trust and trauma centre. The Breast Unit is one of the most advanced in the UK and manages one of the largest caseloads in breast cancer and reconstruction in the UK. The surgical head, Mr Amit Agrawal, and his team have expressed strong interest in introducing the company’s fat storage service into their breast reconstruction workflow and bring its benefits to patients.
The Company’s Chairman & CEO, Antony Rabar, said, “Addenbrooke’s Hospital is a true leader in the field of onco-plastic and reconstructive surgery in the UK with a strong interest in continuous improvement in patient care and improved procedures. The use of fat storage has substantial benefits for hospitals and surgeons, including substantial cost savings as well as delivering improved patient outcomes and satisfaction. Hundreds of women each year undergo life changing reconstructive procedures at the Breast Unit and we are proud that Tissue & Cell Technologies will now be able to provide our world leading fat storage technology to women undergoing reconstructive surgery at Addenbrooke’s, so that they can benefit from using their own all-natural fat in their procedures. We also look forward to collaborating with the team on a number of studies and research as we continue to make advances in clinical outcomes and patient satisfaction.”
The service should be available by September 2024.